Invasive pneumococcal infection (IPI) is the most common serious bacterial infection in human immunodeficiency virus (HIV)-infected children. Data from a population-based pediatric HIV surveillance project were used to determine the incidence of IPI in HIV-infected children and to conduct a case-control study assessing potential risk factors for IPI in HIV-infected children. There were 50 episodes of IPI and a cumulative incidence of 6.1 caseslloo patient-years through age 7 years. Children with IPI were more likely to have a prior AIDS diagnosis (odds ratio, 4.2; 95% confidence interval, 1.2-15.1) and higher levels of IgG and IgM (P = .01) than were controls. In a separate case-control study, the manifestations ofIPI in HIV-infected children were compared with those in HIV-negative controls. Focal complication rates in the 2 groups did not differ; however, HIV-infected children were less likely than controls to have leukocytosis (P < .001) and more likely to have isolates with penicillin resistance (P = .03).
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Invasive bacterial infections are a major cause of illness in children with human immunodeficiency virus (HIV) infection; the most common etiologic organism is Streptococcus pneumoniae [1] [2] [3] [4] [5] [6] . The incidence, clinical course, and infecting serotypes of pneumococcal disease in adult AIDS patients have been described in numerous reports, including some population-based studies [7] [8] [9] [10] [11] [12] . Similar reports of pneumococcal infection in pediatric HIV disease are fewer [6, 13, 14] and do not include population-based comprehensive studies. Risk factors have been identified for other opportunistic infections (e.g., low CD4 cell count for Pneumocystis carinii pneumonia [15] or disseminated Mycobacterium avium-intracellulare infection [16] ) in HIV-infected children, but similar factors for invasive pneumococcal infection (IPI) have not been identified. Questions remain regarding effective and convenient IPI prophylaxis in pediatric HIV disease. Intravenous immunoglobulin (IVIG) has been shown to reduce the incidence ofIPI and other serious bacterial infections in HIV-infected children, but its efficacy has varied [4, 17] . The efficacy of other potential prophylactic measures, including oral antibiotic prophylaxis and pneumococcal vaccination, has not been clearly established [18] [19] [20] [21] .
We used data from a population-based pediatric HIV surveillance program, the Massachusetts Pediatric HIV Spectrum of Disease Project (PSD), to determine the incidence of IPI in HIV-infected children and to conduct a case-control study assessing potential predisposing and protective factors for IPI in the children. The protective factors included immunologic status, prior AIDS-defining diagnosis, IVIG and trimethoprimsulfamethoxazole (TMP-SMZ) prophylaxis, and prior pneumococcal vaccination. To better understand the manifestations of IPI in pediatric HIV disease, we included a subset of these children in a separate case-control analysis comparing clinical and laboratory manifestations, infecting serotypes, and antibiotic sensitivity patterns ofpneumococcal bacteremia in children with and without HIV infection.
Methods
PSD Project. The PSD Project is a multicenter active surveillance study of pediatric HIV infection coordinated by the Centers for Disease Control and Prevention (CDC). Children born after 1 January 1977 who are known to be infected with HIV or who were born to HIV-infected mothers are enrolled in this study at six US sites, including one in Massachusetts. Medical data are abstracted from available records and updated every 6 months; data include information on IPI episodes, CD4 cell counts, immunoglobulin levels, immunization history, and treatment. In Massachusetts, data are abstracted at six tertiary medical centers that contain all of the pediatric HIV clinics in the state. Data collection began in 1989 with an initial retrospective review of all children born after 1977; 348 HIV-infected children have been enrolled in Massachusetts as of July 1994 and are included in this analysis. Patient confidentiality is protected by identifying children only through an alphanumeric code.
Case definition and incidence of IPI in HIV-infected children. Records of the Massachusetts PSD Project were reviewed to identify episodes of IPI occurring in children with perinatal HIV infection through 31 July 1994. Pneumococcal infection was considered invasive if organisms were cultured from the blood, cerebrospinal fluid (CSF), or other nonnally sterile body site. Episodes of IPI occurring~1 month apart in the same subject were considered relapses and were not counted as separate cases. The incidence of IPI in HIV-infected children was calculated by dividing the number of cases of IPI among them by the number of HIV-infected childyears of observation during the study period, stratified by age. Children were censored from further observation at time of death or loss to follow-up.
Potential risk factors for IPI in HIV-infected children. Each child with IPI was age-matched to an HIV-infected control child. Controls had to be alive during the case-patient's IPI episode and have no history of culture-proven invasive bacterial infection. Controls were selected by assigning the child closest in age to the case-patient who met the above criteria. Two-thirds of the cases were matched to controls within 1 month of birth, and the remaining one-third averaged 2.5 months difference between their age and that of their matched control (range, 1-6 months). For children with multiple episodes of IPI, only the first episode was matched because subsequent episodes might not have been independent events.
Infonnation was obtained about the following for case-patients during episodes of IPI and at the corresponding age for their matched controls: sex, race, mode of HIV transmission, prior AIDS-defining diagnoses, current antiretroviral therapy, CD4 cell count, serum levels of IgG, IgA, and IgM, use of IVIG and TMP-SMZ, and prior pneumococcal vaccination. Immunoglobulin levels were compared only among children not receiving IVIG therapy. CD4 cell counts and immunoglobulin levels included in the analysis were obtained within 6 months before the episode of IPI from case patients and within 6 months of the corresponding age from controls.
Clinical and laboratory manifestations of IPI in children with and without HIV irifection. A subset ofthe HIV-infected children with IPI followed at the Children's Hospital AIDS Program (Boston) were compared with controls with pneumococcal bacteremia who were evaluated in the emergency room or general pediatric clinics of Children's Hospital and who were presumed to be HIV negative. Controls were identified by reviewing hospital bacteriology log books of blood isolates. Because the aim of this part of the study was to examine the clinical manifestations of IPI, 2 HIVnegative control patients without a history of immunodeficiency or sickle cell disease were matched to HIV-infected case-patients during each IPI episode by date of positive culture (within 10 days). The following data were obtained from review of hospital records of both HIV-infected and uninfected children: sex, race, age, white blood cell (WBC) count and differential, maximum recorded temperature at presentation, hospitalization and duration, focal complication, and serotype and antibiotic sensitivities (penicillin, erythromycin, and TMP-SMZ) ofthe bacterial isolate. Cases of pneumonia, meningitis, cellulitis, arthritis, and purulent pericarditis were classified as focal complications. Antibiotic resistance was defined using the following National Committee for Clinical Laboratory Standards MIC breakpoints: penicillin,~0.1 j.tg/mL; erythromycin,~1.0 j.tg/mL; and TMP-SMZ,~1.0 j.tg/mL and 19.0 j.tglmL, respectively. Isolates were serotyped at the Massachusetts State Laboratories (Boston), and results were reported in the Danish system of nomenclature.
Statistical analysis. Differences between categorical variables were compared by X 2 analysis or, where appropriate, Fisher's exact test. Differences between continuous variables were assessed by Student's t test.
Results
A total of 348 HIV-infected children were enrolled in the Massachusetts PSD Project through July 1994. Of them, 41 patients with perinatally transmitted HIV infection had a total of 50 IPI episodes between December 1983 and July 1994: 48 episodes were of bacteremia, with or without focus, and 2 involved bacteria cultured from a normally sterile site other than blood (CSF in 1 and pericardial fluid in the other). Age at the IPI episode ranged from 1 to 81 months (median, 30; mean, 32.2). IPI was associated with the deaths of 2 children: 1 died at age 6 years with purulent pericarditis and the other at age 33 months with pneumonia and respiratory arrest associated with pneumococcal sepsis.
Recurrent episodes of IPI occurred in 9 (22%) of the 41 children, with 2-52 months between episodes. None of these children were known to have any other underlying immune condition that would have predisposed them to recurrent IPI. In addition, 2 children had a bacteremic relapse within 1 month of an episode ofbacteremia with pneumonia. Both responded to initial antibiotic therapy with resolution of fever and respiratory symptoms. One child was treated with intravenous (iv) penicillin for 6 days, followed by oral penicillin for 4 days. Two days after completing antibiotic treatment, this patient had recurrent fever and pneumococcal bacteremia with otitis media. Both of his isolates were S. pneumoniae serotype 18 and were sensitive to penicillin. The other child, who had a pneumococcal isolate with low-level resistance to penicillin (MIC = .12 j.tg/mL), was initially treated with iv cefotaxime for 3 days. Because of concurrent Clostridium difJicile diarrhea in this patient, highdose iv penicillin was given for an additional 7 days. Sixteen days after completing antibiotic th~rapy, he had recurrent fever and pneumococcal bacteremia without focus. Both of his pneumococcal isolates were serotype 19. The second isolate also had low-level resistance to penicillin (MIC = .12 J,tg/mL).
Incidence ofIPI in HIV-infected children (table 1). Annual age-specific incidence rates of IPI in HIV-infected children through age 7 years ranged from 2.5 to 9.9 cases/IOO patientyears; the cumulative rate was 6.1 cases/l00 patient-years (95% confidence interval [CI], 4.5-7.7)
Potential risk factors for IPI in HIV-infected children. Demographic characteristics of HIV-infected children with and without IPI were similar (table 2). Table 3 compares background clinical characteristics and use of IVIG and TMP-SMZ and pneumococcal vaccination in HIV-infected children with and without IPI. Only the initial episode of IPI in each patient was included in this analysis. A prior AIDS diagnosis was present in a significantly higher proportion of IPI-positive case-patients than in IPI-negative controls (odds ratio, 4.2; P = .02). The proportion of children with CD4 cell counts in the severe immunosuppression category «750 CD4 cells/mm months and <500 CD4 cells/mm 3 for age 1-5 years, based on 1994 CDC guidelines [22] ) was similar in the IPI-positive and -negative groups, although there was a trend toward a lower mean count among 1-to 5-year-old IPI-positive children.
IgG and IgM levels were significantly higher in IPI-positive children. There were no significant differences in use of IVIG or TMP-SMZ or in pneumococcal vaccination among the 2 groups; however, the groups were not comparable because IPIpositive children had more severe illness. For example, among those who received TMP-SMZ prophylaxis, 7 of II IPI-positive case-patients but only 3 of 13 IPI-negative controls had prior AIDS diagnoses. After data were stratified by prior AIDS diagnosis, a higher proportion of IPI-negative than -positive children had received TMP-SMZ prophylaxis, but the difference was not statistically significant.
Clinical and laboratory manifestations of IPI in children with and without HIV infection. Twenty-six episodes of IPI in 22 HIV-infected children were compared with 52 episodes of pneumococcal bacteremia in HIV-negative controls, who were matched by date of positive culture. One of the 26 episodes in HIV-infected children was a fatal episode of purulent pericarditis due to S. pneumoniae. Although a positive blood culture was not obtained from this child, pneumococcal sepsis was presumptively diagnosed on the basis of clinical criteria and identification of S. pneumoniae from pericardial fluid culture. There were no significant differences in sex or race between children with and without HIV infection (table 4). Table 5 shows a comparison of clinical and laboratory characteristics for HIV-infected and -negative children with pneumococcal bacteremia. The mean age at IPI was higher among case-patients than controls. Maximum recorded fever at presentation was similar in the 2 groups. HIV-negative children had a significantly higher mean WBC count, and a higher proportion had leukocytosis (WBC count >20,000/mm 3 ). Overall rates of Table 4 . Sex and race of HIV-positive and -negative children with invasive pneumococcal infection (IPI).
HIV-infected children in this study had a high incidence of IPI (6.1 cases/100 patient-years) through age 7. These rates are comparable to levels of pneumococcal bacteremia reported in children with sickle cell disease (6.1/100 person-years in children <3 years old [23] and 5.9/100 person-years in those <6 focal or nonfocal infections did not differ; however, HIV-infected children were hospitalized with episodes of IPI significantly more frequently than were mv-negative children.
The distribution of serotypes of S. pneumoniae were similar in children with and without HIV infection. Aside from 1 serotype 31 pneumococcal isolate in an HIV-negative child, the serotypes of all blood isolates from both HIV-infected and uninfected children were among the 23 serotypes included in the currently available pneumococcal vaccine. Penicillin resistance was found in a greater proportion of pneumococcal isolates from HIV-infected than from uninfected children (20% vs. 2%, P = .03; table 6).
years old [24] ), and 100-to 300-fold the rates of IPI reported in children <5 years old in community-based studies in the United States and in other countries (18 to 60 cases/1 00,000/ year [25] [26] [27] [28] [29] [30] ). Children in the general population are at highest risk for IPI before age 2 years, after which incidence rates drop significantly [31] ; however, among HIV-infected children, the incidence of IPI remained high through age 7 years.
We report an incidence rate of IPI in HIV-infected children that is slightly but not significantly lower than the rate found in a previously published study by Farley et al. [13] (11.3/100 patient-years; 95% CI, 4.7-17.9). The number of patients and length of observation were considerably larger in our study than in the previous study (815 vs. 89 patient-years). However, our incidence rate was based on both retrospective (up to 1989) and prospective data (after 1989, when active surveillance by PSD Project began), while the incidence rate reported by Farley et al. [13] was based on only prospective data. Our slightly lower incidence rate might be due to some undetected cases ofIPI, particularly from the earlier years ofthe AIDS epidemic, when diagnosis of HIV infection was more common among children of an older age. Blood cultures may be more likely to be obtained, and pneumococcal bacteremia thus identified, among febrile HIV-infected than HIV-negative children. If so, undetected cases of IPI might have occurred in children before· their HIV infection was diagnosed. Using only prospective data collected after HIV infection was diagnosed, we found a slightly higher cumulative incidence (8.2 cases/100 patientyears through age 3 years and 7.1 through age 7 years).
Our lower incidence rate might also be due in part to the lower proportion of blacks in our study population (59% vs. 92% in the study of Farley et al. [13] ). The race-specific incidence of IPI in blacks was more than twice that in whites in our study. Previous studies have shown a higher incidence of IPI among blacks than whites, even after controlling for sickle cell status [26, 32] .
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HIV-negative (n = 52 episodes) In contrast to a previous report that found no significant differences in immunoglobulin levels between HIV-infected children with and without IPI [13] , we found significantly higher IgG and IgM levels in those with IPI. Elevated levels of presumably qualitatively defective serum immunoglobulins associated with polyclonal B cell activation have been described in HIV-infected adults and children [33] [34] . Our finding of higher IgG and IgM levels in HIV-infected children with IPI might reflect more intense polyclonal B cell activation associated with a greater defect in humoral immunity in this group.
Most first episodes of IPI (26/41, 63%) in HIV-infected children occurred in those without a diagnosis of AIDS; however, more advanced HIV disease (as defined by a prior diagnosis of AIDS) was associated with a higher risk of IPI (odds ratio, 4.2; 95% CI, 1.2-15.1). In the age category with the greatest number of children (1-5 years), HIV-infected children with IPI tended to have lower CD4 cell counts than children without IPI. These findings are consistent with previous studies that reported a higher risk of IPI in HIV-infected adult patients with AIDS [8, 9] or lower CD4 cell counts [12] . Our results also support a previous retrospective review of bacterial infections in HIV-infected children that found an increased risk for bacterial infections in children with low absolute CD4 cell counts [3] . In contrast, a smaller, prospective study of IPI in HIV-infected children concluded that HIV disease progression was not useful in identifying children at risk for invasive pneumococcal disease [13] .
Several recent studies have evaluated the efficacy of various potential measures to prevent IPI in HIV-infected children. One randomized, double-blind, placebo-controlled trial demonstrated that periodic infusions of IVIG helped prevent serious bacterial infections, especially invasive pneumococcal disease, in HIVinfected children with >200 CD4 cells/mm 3 [4] . A similar randomized trial also documented the overall protective effect of IVIG but failed to find any additional benefit in the subset of children also receiving TMP-SMZ [17] . A reduced incidence of pneumococcal bacteremia in HIV-infected children after routine prophylaxis with penicillin has also been reported [18] .
Pneumococcal vaccination is recommended for HIV-infected children~2 years old [35] . Decreased antibody response to pneumococcal vaccine in these children has been reported [19] [20] [21] ; however, no controlled studies have examined the clinical efficacy of the vaccination. The development of a conjugate pneumococcal vaccine holds promise for more effective immunization. Because of the high incidence of IPI in HIVinfected children, they might be an appropriate population in which to conduct initial studies on the efficacy of candidate conjugate pneumococcal vaccines.
In our study, confounding, bias, and small sample size all likely contributed to the lack of an observed protective effect of IVIG, TMP-SMZ, and, perhaps, pneumococcal vaccination against IPI. Prior AIDS diagnosis, for example, was correlated with prophylactic treatment (e.g., TMP-SMZ) and ass09iated with IPI in our study population. Stratification by prior AIDS diagnosis, however, did not show that TMP-SMZ or other preventive therapies had a statistically significant effect, although numbers in each stratum were small. The apparent lack of protection from pneumococcal vaccination might also be attributable to recall bias; for example, prior vaccination may be more likely to be documented in the medical record of a child after an episode of IPI. Of interest, for children who had more than one episode of IPI, use of prophylactic therapy was higher with repeat than first episodes (50% vs. 28% for TMP-SMZ, 50% vs. 13% for IVIG, and 80% vs. 50% forpneumococcal vaccination), suggesting that these prophylactic measures are less beneficial among children with a known history of IPI who are at high risk for reinfection.
In contrast to previous reports that found no difference in laboratory manifestations ofIPI in HIV-infected and uninfected children [13, 14] , we found a significantly lower mean WBC count in HIV-infected children. Because we did not have baseline counts for the HIV-infected subjects, we cannot tell whether these WBC counts represent a significant increase over baseline. The 2 groups otherwise had similar clinical manifestations of IPI, including similar degrees of fever and overall rates of focal complications. Of note, however, 2 HIV-infected children died, 1 of purulent pericarditis and the other of pneumonia with respiratory arrest. Aside from these 2 cases, the clinical course of IPI in HIV-infected children was generally relatively benign, and most case-patients were treated successfully with conventional antibiotic therapy. Nevertheless, almost 75% of children were hospitalized for their episode of IPI.
We found that the rate of penicillin resistance was significantly higher in isolates from HIV-infected children than in those from children without HIV. In contrast, a previous study of systemic pneumococcal infection in HIV-infected children found no cases of penicillin resistance among 26 isolates [14] . Our findings are not surprising if children with HIV infection are more likely than HIV-negative children to be exposed to antibiotics, as might be anticipated. In an era of increasing resistance of S. pneumoniae to antimicrobial agents, these findings present potential difficulties for plans to study or implement oral antibiotic prophylaxis against IPI in HIV-infected children.
We conclude that IPI is amajor cause of morbidity in HIVinfected children, with a high incidence rate continuing among older children (2-6 years old). Associated risk factors for IPI in HIV-infected children include a diagnosis of AIDS and higher levels of IgG and IgM. Given the retrospective nature of our study and likely insufficient numbers to control for potential confounding factors, we cannot adequately assess whether TMP-SMZ, IVIG, and pneumococcal vaccination protect against IPI in HIV-infected children. Notable differences in manifestations of pneumococcal bacteremia between HIV-infected and uninfected children in our study include a lower WBC count and higher rate of pneumococcal resistance to penicillin.
